What's new

Hepatitis C and Diabetes

DrJay2001

now at peace
Dear All,

As many of you know Hepatitis C is a major problem in America effecting some 8,000,000 people.

As the article below points out, the inflammation related to HCV causes the release of an immune lymphokine called Tumor Necrosis Factor (TNF) that blocks insulin receptors in the liver.

Guess what drug markedly reduces TNF? Cannabis.

Yours,
Dr. jay





Hepatitis C Virus Directly Involved in Insulin Resistance



NEW YORK (Reuters Health) Mar 09 - Hepatitis C virus (HCV) is directly involved in the development of insulin resistance, according to a report in the March issue of Gastroenterology.

HCV infection has been associated with type 2 diabetes, the authors explain, but a definite causative relationship between HCV infection and diabetes has not been established.

Dr. Kazuhiko Koike, and colleagues from University of Tokyo, studied the role of HCV in the development of diabetes using transgenic mice that carry the core gene of HCV.

"Hyperinsulinemia was observed in the core gene transgenic mice as early as 1 month old," the authors report. Insulin resistance was observed by the age of 2 months.

Administration of glucose to core gene transgenic mice revealed only mild and statistically insignificant glucose intolerance compared with control mice, the results indicate, but transgenic mice fed a high-fat diet developed overt diabetes.

Insulin resistance depended chiefly on the shortage of insulin action on the liver, the researchers note, whereas skeletal muscle contributed little to the development of insulin resistance.

Suppression of insulin action in the liver resulting from TNF-alpha-mediated suppression of tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) is at least one of the mechanisms of insulin resistance in this model, the investigators report, and TNF-alpha blockade restored insulin sensitivity.

The authors conclude, "The HCV core protein induces insulin resistance in transgenic mice without gain in body weight at young age. These results indicate a direct involvement of HCV per se in the pathogenesis of diabetes in patients with HCV infection and provide a molecular basis for insulin resistance in such a condition."

"The study makes a major contribution by showing that hepatic insulin resistance can be induced solely by expression of the HCV core protein, and that signaling abnormalities in the insulin receptor-IRS-1 pathway are present before the development of steatosis," write Dr. Steven A. Weinman and Dr. L. Maria Belalcazar from University of Texas Medical Branch, Galveston, in a related editorial.

"The article...makes an important contribution to putting the HCV-diabetes association on a mechanistic footing, thus elevating it from a curious association to an important disease process."

Gastroenterology 2004;126:840-848,917-919.
 

DrJay2001

now at peace
Here's just one recent study that demonstrates the role of cannabinoids in reducing TNF (and other proinflammatory cytokines) in a murine (mouse) model of MS.

Yours,
Dr. Jay

J Clin Invest. 2003 Apr;111(8):1231-40. Related Articles, Links


Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212.

Croxford JL, Miller SD.

Department of Microbiology-Immunology, Interdepartmental Immunobiology Center, Northwestern University Medical School, 303 E. Chicago Avenue, Chicago, IL 60611, USA.

Theiler murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) is a mouse model of chronic-progressive multiple sclerosis (MS) characterized by Th1-mediated CNS demyelination and spastic hindlimb paralysis. Existing MS therapies reduce relapse rates in 30% of relapsing-remitting MS patients, but are ineffective in chronic-progressive disease, and their effects on disability progression are unclear. Experimental studies demonstrate cannabinoids are useful for symptomatic treatment of spasticity and tremor in chronic-relapsing experimental autoimmune encephalomyelitis. Cannabinoids, however, have reported immunosuppressive properties. We show that the cannabinoid receptor agonist, R+WIN55,212, ameliorates progression of clinical disease symptoms in mice with preexisting TMEV-IDD. Amelioration of clinical disease is associated with downregulation of both virus and myelin epitope-specific Th1 effector functions (delayed-type hypersensitivity and IFN-gamma production) and the inhibition of CNS mRNA expression coding for the proinflammatory cytokines, TNF-alpha, IL1-beta, and IL-6. Clinical trials investigating the therapeutic potential of cannabinoids for the symptomatic treatment of MS are ongoing, and this study demonstrates that they may also have potent immunoregulatory properties.
 

DrJay2001

now at peace
You're welcome! I have both Type 1 diabetes and Hepatitis C. Even with a huge viral count, cannabis has protected my liver as evidenced by two biopsies.

Yours,
Dr. Jay
 

LL84

Member
drjay2001-
organic coconut milk and raw coconut is really good for you and will help kill the viral count. i think it would even be more beneficial than cannabis, i dont know though. i do know that when the panama canal was being built the locals were the ones surviving from malaria because the had coconut in there diets. check it out though. i know people that eat it weekly and especially when they tell they are coming onto a cold or flu.
 
P

pSi007

fuk, man... 1 in 50 people have HepC. 1 in 75 people have HIV...


I cry for those and some, I have had their blood on my hands without worry, as I am paramedic but still... I am happy to say after all of that, I am HIV and Hep C negative. I will never stop thinking and fighting a good cause.


Dr. Jay, if you can hear me in some far off place, remember me as a soldier and I will stand. I`m sure you remember me and all of us who made a stand.
 
G

guest

reposted from over here:

http://www.icmag.com/ic/showthread.php?p=2006043#post2006043

My A1c is 6.2 I think that the max I ever hit was ~7.6
GLU 95 (that three month average one) usually ~150
CHOL 169
TRIG 131 (max reading of ~800)
bp in the doctors office was 120/78 One year ago it was 235/135

FYI that is the entire metabolic syndrome. Which is what GW pharm noted in their human studies.

The way it works is that cannabinoids lower the levels of TCF. TCF causes inflammation of the pancreas. With the lowering of the TCF levels, there is a reduction of inflammation. What is left of the pancreas moves toward normal function. In addition there is a gain in insulin sensitivity in the rest of the body.

It is a reversal of the progression of the disease.

I understand your point. I only mentioned mine because you seem to be someone of medical knowledge. Yet lacking in awareness of what cannabinoids can do for people.
 
G

guest

Human trials with THCV against type 2 diabetes:

Highly Promising Results for New GW Cannabinoid Treatments for Diabetes and Related Metabolic Disorders

22/01/2008


Preparations underway for commencement of Phase II trials in 2008

Porton Down, UK, 22 January 2008: GW Pharmaceuticals plc (AIM: GWP) announces that it has generated highly promising results in both pre-clinical pharmacology studies and a Phase I trial of a new potential cannabinoid treatment for type 2 diabetes and related metabolic disorders. This research is part of a programme being conducted by GW to evaluate selected cannabinoids in a range of therapeutic areas.

GW’s initial cannabinoid target in this field, delta-9-tetrahydrocannabivarin (THCV), has successfully completed extensive pre-clinical pharmacology studies and its first Phase I clinical trial.

The pre-clinical studies have yielded highly promising findings. Recent results in several models of diabetes show desirable effects on plasma insulin, leptin and adiponectin levels, hormones of particular relevance to the development and treatment of diabetes, especially in obese individuals. In addition, we have seen a reduction in total cholesterol with an increase in the proportion of HDL (good) cholesterol.

The recently completed Phase I trial was a randomised, double blind, placebo controlled, dose escalation, safety and tolerability study of single doses of THCV in twelve healthy volunteer subjects. This trial showed that the study medication was well tolerated at target therapeutic doses and demonstrated a satisfactory safety profile.

Following on from this first study, GW is now preparing for a Phase IIa multiple dose study in type 2 diabetic patients in 2008.

These recent results add to previous findings showing effects on body weight, body fat content, energy expenditure, food intake, and other obesity-related parameters.

Dr Stephen Wright, R&D Director of GW, said, “These new results confirm that GW’s proprietary plant-based cannabinoids have significant potential as treatments in this important branch of therapeutics. We are now ready to build upon the pre-clinical data, as well as the Phase I trial results, by entering Phase II proof of principle studies during 2008.”

Dr Geoffrey Guy, Chairman, said, ”This exciting research programme is a further example of the range of potential for GW’s cannabinoids as new medicines. We believe that our research in the field of metabolic disorders represents a significant opportunity for GW and that it has the potential to be an important new area for future collaboration with partners.”

http://production.investis.com/gwp/pressreleases/currentpress/2008-01-22a/
 
G

guest

And I should mention that I consume about 3/4 cup of sugar/day in my ~30 cups of coffee.
 
D

dankbudz

i just about flipped shit when i seen who posted this thread..thinking it was a new one
 

Tanuvan

Member
I hadn't considered the effects of cannabinoids/TNF on individuals with insulin insensitivity.

From what I have seen...on one hand literature states that TNF concentrations cause inflammation of the islets, but at the same time, protects against IDDM.

"In transgenic mice, TNF alpha expression on the islets resulted in massive insulitis, composed of CD4+ T cells, CD8+ T cells, and B cells. Despite infiltration of considerable number of lymphoid cells in islets, expression of TNF alpha protected NOD mice from IDDM. ...These data establish a mechanism of TNF alpha action and provide evidence that local expression of TNF alpha protects NOD mice from autoimmune diabetes by preventing the development of autoreactive islet-specific T cells. "

So are the cannabinoids increasing or decreasing the levels of TNF alpha? I'm curious to know the pathways involved in the GW Pharma Model. I will definitely keep my eye on this.

I would have replied earlier, but kept getting "You may only make 10 replies every 24 hours. Please try again later."

BTW, the second set of labs are impressive. Is this without oral medication?
 
G

guest

Tanuvan said:
So are the cannabinoids increasing or decreasing the levels of TNF alpha? I'm curious to know the pathways involved in the GW Pharma Model. I will definitely keep my eye on this.
Results from researchers in looking at type 1 showed a 70% reduction in TNF.

BTW, the second set of labs are impressive. Is this without oral medication?
Correct. While I showed great improvement in sugar readings, my best improvements were in the areas of bp and triglycerides.

I was using a topical application of cannabinoids.
 
Last edited:

Latest posts

Latest posts

Top